Top

Published in:

01-12-2021 | Metronidazole | Review

Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment

Authors: Lenka A. Vodstrcil, Christina A. Muzny, Erica L. Plummer, Jack D. Sobel, Catriona S. Bradshaw

Published in: BMC Medicine | Issue 1/2021

Abstract

Bacterial vaginosis (BV) is the most common vaginal dysbiosis to affect women globally, yet an unacceptably high proportion of women experience BV recurrence within 6 months of recommended antibiotic therapy. The low rate of sustained cure highlights our limited understanding of the pathogenesis of BV recurrence, which has been attributed to possible persistence and re-emergence of BV-associated bacteria (BVAB) or a BV-associated biofilm following antimicrobials and/or reinfection occurring from sexual partners.

There is a robust body of evidence to support the exchange of bacteria between partners during sexual activity, and while the hypothesis that women treated for BV are subsequently reinfected with BVAB following sex with an untreated sexual partner is not new, failure of past partner treatment trials has eroded confidence in this concept. If reinfection is a key driver of recurrence, current antimicrobial regimens directed to women alone are unlikely to achieve a high level of sustained cure, and the approach of partner treatment to reduce reinfection is justified. In this manuscript, we present the molecular and epidemiological evidence that underlies the hypothesis that BV is sexually transmitted, and summarise why research that continues to consider sexual partnerships is necessary. We also outline the significant barriers and challenges that we have identified while undertaking partner treatment studies, and we discuss the factors that impact on our ability to determine their effectiveness.

Ultimately, the pathogenesis of BV recurrence is likely to be multifaceted and not attributable to a single mechanism in all women. If we are to achieve sustained cure for women, it is likely that combined and individualised approaches to eradicate BVAB, support an optimal vaginal microbiome, and prevent reinfection from partners will be required.

Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–11. https://doi.org/10.1097/OLQ.0000000000000972.CrossRefPubMed

Koumans EH, Markowitz LE, Berman SM, St Louis ME. A public health approach to adverse outcomes of pregnancy associated with bacterial vaginosis. Int J Gynaecol Obstet. 1999;67:S29–33. https://doi.org/10.1016/S0020-7292(99)00136-8.CrossRefPubMed

Brotman RM, Klebanoff MA, Nansel TR, Yu KF, Andrews WW, Zhang J, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202(12):1907–15. https://doi.org/10.1086/657320.CrossRefPubMedPubMedCentral

Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9(6):e1001251. https://doi.org/10.1371/journal.pmed.1001251.CrossRefPubMedPubMedCentral

Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis. 2015;61(2):260–9. https://doi.org/10.1093/cid/civ298.CrossRefPubMedPubMedCentral

Alisoltani A, Manhanzva MT, Potgieter M, Balle C, Bell L, Ross E, Iranzadeh A, du Plessis M, Radzey N, McDonald Z, et al. Microbial function and genital inflammation in young South African women at high risk of HIV infection. Microbiome 2020;8:165. https://doi.org/10.1186/s40168-020-00932-8.

Skafte-Holm A, Humaidan P, Bernabeu A, Lledo B, Jensen JS, Haahr T. The association between vaginal dysbiosis and reproductive outcomes in sub-fertile women undergoing IVF-treatment: a systematic PRISMA review and meta-analysis. Pathogens. 2021;10(3):295.

Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14–22. https://doi.org/10.1016/0002-9343(83)91112-9.CrossRefPubMed

Klebanoff MA, Schwebke JR, Zhang J, Nansel TR, Yu KF, Andrews WW. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004;104(2):267–72. https://doi.org/10.1097/01.AOG.0000134783.98382.b0.CrossRefPubMed

10.

Bilardi J, Walker S, McNair R, Mooney-Somers J, Temple-Smith M, Bellhouse C, et al. Women’s management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016;11(3):e0151794. https://doi.org/10.1371/journal.pone.0151794.CrossRefPubMedPubMedCentral

11.

Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899–911. https://doi.org/10.1056/NEJMoa043802.CrossRefPubMed

12.

Fettweis JM, Serrano MG, Sheth NU, Mayer CM, Glascock AL, Brooks JP, et al. Species-level classification of the vaginal microbiome. BMC Genomics. 2012;13(Suppl 8):S17.CrossRef

13.

Gajer P, Brotman RM, Bai G, Sakamoto J, Schutte UM, Zhong X, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132ra152.CrossRef

14.

McKinnon LR, Achilles SL, Bradshaw CS, Burgener A, Crucitti T, Fredricks DN, et al. The evolving facets of bacterial vaginosis: Implications for HIV transmission. AIDS Res Hum Retroviruses. 2019;35(3):219–28. https://doi.org/10.1089/aid.2018.0304.CrossRefPubMedPubMedCentral

15.

Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. PNAS USA. 2011;108(Suppl 1):4680–7. https://doi.org/10.1073/pnas.1002611107.CrossRefPubMed

16.

Muzny CA, Taylor CM, Swords WE, Tamhane A, Chattopadhyay D, Cerca N, Schwebke JR. An updated conceptual model on the pathogenesis of bacterial vaginosis. J Infect Dis. 2019;220(9):1399–405. https://doi.org/10.1093/infdis/jiz342.

17.

UK National Guideline for the management of Bacterial Vaginosis. 2012:1–15. https://www.bashhguidelines.org/media/1041/bv-2012.pdf.

18.

Workowski KA, Bolan GA. Sexually transmitted disease treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-3):1–137.

19.

Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258–72. https://doi.org/10.1177/0956462418785451.CrossRefPubMed

20.

Vaginitis in nonpregnant patients. ACOG Practice Bulletin, Number 215. Obstet Gynecol. 2020;135(1):e1–e17.CrossRef

21.

Koumans EH, Markowitz LE, Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35(Suppl 2):S152–72. https://doi.org/10.1086/342103.CrossRefPubMed

22.

Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;3:CD006055.

23.

Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis. 1993;167(3):783–4. https://doi.org/10.1093/infdis/167.3.783.CrossRefPubMed

24.

Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–89. https://doi.org/10.1086/503780.CrossRefPubMed

25.

Swidsinski A, Mendling W, Loening-Baucke V, Swidsinski S, Dorffel Y, Scholze J, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97 e91–6.CrossRef

26.

Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777–86. https://doi.org/10.1093/cid/cis1030.CrossRefPubMed

27.

Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis. 2015;15(1):292. https://doi.org/10.1186/s12879-015-1027-4.CrossRefPubMedPubMedCentral

28.

Muzny CA, Laniewski P, Schwebke JR, Herbst-Kralovetz MM. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr Opin Infect Dis. 2020;33(1):59–65. https://doi.org/10.1097/QCO.0000000000000620.CrossRefPubMedPubMedCentral

29.

Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906–15. https://doi.org/10.1056/NEJMoa1915254.CrossRefPubMedPubMedCentral

30.

Ratten LK, Plummer EL, Murray GL, Danielewski J, Fairley CK, Garland SM, et al. Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study. BJOG. 2021;128(4):756–67. https://doi.org/10.1111/1471-0528.16430.CrossRefPubMed

31.

Eren AM, Zozaya M, Taylor CM, Dowd SE, Martin DH, Ferris MJ. Exploring the diversity of Gardnerella vaginalis in the genitourinary tract microbiota of monogamous couples through subtle nucleotide variation. PLoS One. 2011;6(10):e26732. https://doi.org/10.1371/journal.pone.0026732.CrossRefPubMedPubMedCentral

32.

Mandar R, Punab M, Borovkova N, Lapp E, Kiiker R, Korrovits P, et al. Complementary seminovaginal microbiome in couples. Res Microbiol. 2015;166(5):440–7. https://doi.org/10.1016/j.resmic.2015.03.009.CrossRefPubMed

33.

Zozaya M, Ferris MJ, Siren JD, Lillis R, Myers L, Nsuami MJ, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome. 2016;4(1):16. https://doi.org/10.1186/s40168-016-0161-6.CrossRefPubMedPubMedCentral

34.

Plummer EL, Vodstrcil LA, Danielewski JA, Murray GL, Fairley CK, Garland SM, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: acceptability, tolerability and impact on the genital microbiota of couples - a pilot study. PLoS One. 2018;13(1):e0190199. https://doi.org/10.1371/journal.pone.0190199.CrossRefPubMedPubMedCentral

35.

Muzny CA, Van Der Pol W, Lefkowitz E, Ghosh A, Li M, Redden D, et al. 2408 Genital microbiomes of women with recurrent bacterial vaginosis and their regular male sexual partner. J Clin Translat Sci. 2018;2(S1):13. https://doi.org/10.1017/cts.2018.78.CrossRef

36.

Vodstrcil LA, Walker SM, Hocking JS, Law M, Forcey DS, Fehler G, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission. Clin Infect Dis. 2015;60(7):1042–53. https://doi.org/10.1093/cid/ciu1130.CrossRefPubMed

37.

Plummer EL, Vodstrcil LA, Fairley CK, Tabrizi SN, Garland SM, Law MG, et al. Sexual practices have a significant impact on the vaginal microbiota of women who have sex with women. Sci Rep. 2019;9(1):19749. https://doi.org/10.1038/s41598-019-55929-7.CrossRefPubMedPubMedCentral

38.

Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17(8):e235–79. https://doi.org/10.1016/S1473-3099(17)30310-9.CrossRefPubMed

39.

Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol. 1955;69(5):962–76. https://doi.org/10.1016/0002-9378(55)90095-8.CrossRefPubMed

40.

Criswell BS, Ladwig CL, Gardner HL, Dukes CD. Haemophilus vaginalis: vaginitis by inoculation from culture. Obstet Gynecol. 1969;33(2):195–9.PubMed

41.

Patterson JL, Stull-Lane A, Girerd PH, Jefferson KK. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiology. 2010;156(Pt 2):392–9. https://doi.org/10.1099/mic.0.034280-0.CrossRefPubMedPubMedCentral

42.

Gardner HL, Dukes CD. Hemophilus vaginalis vaginitis. Ann N Y Acad Sci. 1959;83:280–9. https://doi.org/10.1111/j.1749-6632.1960.tb40901.x.CrossRefPubMed

43.

Pheifer TA, Forsyth PS, Durfee MA, Pollock HM, Holmes KK. Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole. N Engl J Med. 1978;298(26):1429–34. https://doi.org/10.1056/NEJM197806292982601.CrossRefPubMed

44.

Dawson SG, Ison CA, Csonka G, Easmon CS. Male carriage of Gardnerella vaginalis. Br J Vener Dis. 1982;58(4):243–5. https://doi.org/10.1136/sti.58.4.243.CrossRefPubMedPubMedCentral

45.

Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. Jama. 1985;254(8):1046–9. https://doi.org/10.1001/jama.1985.03360080058029.CrossRefPubMed

46.

Vejtorp M, Bollerup AC, Vejtorp L, Fanoe E, Nathan E, Reiter A, et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynaecol. 1988;95(9):920–6. https://doi.org/10.1111/j.1471-0528.1988.tb06581.x.CrossRefPubMed

47.

Mengel MB, Berg AO, Weaver CH, Herman DJ, Herman SJ, Hughes VL, et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J Fam Pract. 1989;28(2):163–71.PubMed

48.

Moi H, Erkkola R, Jerve F, Nelleman G, Bymose B, Alaksen K, et al. Should male consorts of women with bacterial vaginosis be treated? Genitourin Med. 1989;65(4):263–8. https://doi.org/10.1136/sti.65.4.263.CrossRefPubMedPubMedCentral

49.

Vutyavanich T, Pongsuthirak P, Vannareumol P, Ruangsri RA, Luangsook P. A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis. Obstet Gynecol. 1993;82(4 Pt 1):550–4.PubMed

50.

Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med. 1997;73(4):267–70. https://doi.org/10.1136/sti.73.4.267.CrossRefPubMedPubMedCentral

51.

Schwebke J, Lensing S, Lee J, Muzny CA, Pontius A, Woznicki N, Aguin T, Sobel JD. Treatment of male sexual partners of women with bacterial vaginosis (BV); a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2021;73(3):e672–9.

52.

Vodstrcil LA, Plummer EL, Doyle M, Fairley CK, McGuiness C, Bateson D, et al. Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence. BMC Infect Dis. 2020;20(1):834. https://doi.org/10.1186/s12879-020-05563-w.CrossRefPubMedPubMedCentral

53.

Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822–30. https://doi.org/10.1097/OLQ.0b013e3182631d89.CrossRefPubMed

54.

Potter J. Should sexual partners of women with bacterial vaginosis receive treatment? Br J Gen Pract. 1999;49(448):913–8.PubMedPubMedCentral

55.

Amaya-Guio J, Viveros-Carreno DA, Sierra-Barrios EM, Martinez-Velasquez MY, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701.PubMed

56.

Larsson PG, Platz-Christensen JJ, Sundstrom E. Is bacterial vaginosis a sexually transmitted disease? Int J STD AIDS. 1991;2(5):362–4. https://doi.org/10.1177/095646249100200511.CrossRefPubMed

57.

Bukusi EA, Cohen CR, Meier AS, Waiyaki PG, Nguti R, Njeri JN, et al. Bacterial vaginosis: risk factors among Kenyan women and their male partners. Sex Transm Dis. 2006;33(6):361–7. https://doi.org/10.1097/01.olq.0000200551.07573.df.CrossRefPubMed

58.

Fethers KA, Fairley CK, Morton A, Hocking JS, Hopkins C, Kennedy LJ, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662–70. https://doi.org/10.1086/648092.CrossRefPubMed

59.

Fethers KA, Fairley CK, Morton A, Hocking JS, Fehler G, Kennedy LJ, et al. Low incidence of bacterial vaginosis in cohort of young Australian women. Sex Transm Dis. 2011;38(2):124–6. https://doi.org/10.1097/OLQ.0b013e3181f0bc37.CrossRefPubMed

60.

Vodstrcil LA, Twin J, Garland SM, Fairley CK, Hocking JS, Law MG, et al. The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS One. 2017;12(2):e0171856. https://doi.org/10.1371/journal.pone.0171856.CrossRefPubMedPubMedCentral

61.

Francis SC, Crucitti T, Smekens T, Hansen CH, Andreasen A, Jespers V, et al. The vaginal microbiota among adolescent girls in Tanzania around the time of sexual debut. Front Cell Infect Microbiol. 2020;10:305. https://doi.org/10.3389/fcimb.2020.00305.CrossRefPubMedPubMedCentral

62.

Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426–35. https://doi.org/10.1086/592974.CrossRefPubMed

63.

Warner L, Newman DR, Austin HD, Kamb ML, Douglas JM Jr, Malotte CK, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol. 2004;159(3):242–51. https://doi.org/10.1093/aje/kwh044.CrossRefPubMed

64.

Forcey DS, Vodstrcil LA, Hocking JS, Fairley CK, Law M, McNair RP, et al. Factors associated with bacterial vaginosis among women who have sex with women: A systematic review. PLoS One. 2015;10(12):e0141905. https://doi.org/10.1371/journal.pone.0141905.CrossRefPubMedPubMedCentral

65.

Schwebke J, Desmond RA. Risk Factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis. 2005;32(11):654–8. https://doi.org/10.1097/01.olq.0000175396.10304.62.CrossRefPubMed

66.

Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One. 2010;5(6):e11139. https://doi.org/10.1371/journal.pone.0011139.CrossRefPubMedPubMedCentral

67.

Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;18(6):702–8. https://doi.org/10.1097/EDE.0b013e3181567eaa.CrossRefPubMed

68.

Gallo MF, Warner L, King CC, Sobel JD, Klein RS, Cu-Uvin S, et al. Association between semen exposure and incident bacterial vaginosis. Infect Dis Obstet Gynecol. 2011;2011:842652.PubMedPubMedCentral

69.

Muzny CA, Schwebke JR. Suspected heterosexual transmission of bacterial vaginosis without seminal fluid exposure. Sex Transm Dis. 2014;41(1):58–60. https://doi.org/10.1097/OLQ.0000000000000057.CrossRefPubMed

70.

Plummer EL, Vodstrcil LA, Murray GL, Fairley CK, Danielewski JA, Garland SM, et al. Gardnerella vaginalis clade distribution is associated with behavioural practices and Nugent Score in women who have sex with women. J Infect Dis. 2020;221(3):454–63. https://doi.org/10.1093/infdis/jiz474.CrossRefPubMed

71.

Muzny CA, Blanchard E, Taylor CM, Aaron KJ, Talluri R, Griswold ME, et al. Identification of key bacteria involved in the induction of incident bacterial vaginosis: a prospective study. J Infect Dis. 2018;218(6):966–78. https://doi.org/10.1093/infdis/jiy243.CrossRefPubMedPubMedCentral

72.

Muzny CA, Lensing SY. Aaron KJ. Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women. Sex Transm Infect: Schwebke JR; 2019.

73.

Berger BJ, Kolton S, Zenilman JM, Cummings MC, Feldman J, McCormack WM. Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin Infect Dis. 1995;21(6):1402–5. https://doi.org/10.1093/clinids/21.6.1402.CrossRefPubMed

74.

Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis. 2002;185(9):1307–13. https://doi.org/10.1086/339884.CrossRefPubMed

75.

Bradshaw CS, Walker SM, Vodstrcil LA, Bilardi JE, Law M, Hocking JS, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis. 2014;209(10):1562–72. https://doi.org/10.1093/infdis/jit664.CrossRefPubMed

76.

Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis. 2009;199(5):680–3. https://doi.org/10.1086/596632.CrossRefPubMed

77.

Vodstrcil LA, Plummer ME, Fairley CK, Tachedjian G, Law MG, Hocking JS, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep. 2019;9(1):3555. https://doi.org/10.1038/s41598-019-39879-8.CrossRefPubMedPubMedCentral

78.

Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol. 2004;191(6):1898–906. https://doi.org/10.1016/j.ajog.2004.06.089.CrossRefPubMed

79.

Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213–9. https://doi.org/10.1086/509577.CrossRefPubMed

80.

Piot P, Van Dyck E, Peeters M, Hale J, Totten PA, Holmes KK. Biotypes of Gardnerella vaginalis. J Clin Microbiol. 1984;20(4):677–9. https://doi.org/10.1128/jcm.20.4.677-679.1984.CrossRefPubMedPubMedCentral

81.

Nelson DE, Dong Q, Van Der Pol B, Toh E, Fan B, Katz BP, et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One. 2012;7(5):e36298. https://doi.org/10.1371/journal.pone.0036298.CrossRefPubMedPubMedCentral

82.

Liu CM, Hungate BA, Tobian AA, Ravel J, Prodger JL, Serwadda D, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. MBio. 2015;6(3):e00589. https://doi.org/10.1128/mBio.00589-15.CrossRefPubMedPubMedCentral

83.

Plummer EL, Vodstrcil LA, Fairley CK, Danielewski JA, Murray GL, Doyle M, et al. The impact of concurrent partner treatment for bacterial vaginosis on the genital microbiota of heterosexual couples: A pilot study. Sex Transm Infect. 2021;97(Suppl 1):A18.

84.

Swidsinski A, Doerffel Y, Loening-Baucke V, Swidsinski S, Verstraelen H, Vaneechoutte M, et al. Gardnerella biofilm involves females and males and is transmitted sexually. Gynecol Obstet Invest. 2010;70(4):256–63. https://doi.org/10.1159/000314015.CrossRefPubMed

85.

Swidsinski A, Dorffel Y, Loening-Baucke V, Mendling W, Verstraelen H, Dieterle S, et al. Desquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol. 2010;59(3):399–404. https://doi.org/10.1111/j.1574-695X.2010.00688.x.CrossRefPubMed

86.

Gray RH, Wawer MJ, Serwadda D, Kigozi G. The role of male circumcision in the prevention of human papillomavirus and HIV infection. J Infect Dis. 2009;199(1):1–3. https://doi.org/10.1086/595568.CrossRefPubMed

87.

Price LB, Liu CM, Johnson KE, Aziz M, Lau MK, Bowers J, et al. The effects of circumcision on the penis microbiome. PLoS One. 2010;5(1):e8422. https://doi.org/10.1371/journal.pone.0008422.CrossRefPubMedPubMedCentral

88.

Liu CM, Hungate BA, Tobian AA, Serwadda D, Ravel J, Lester R, et al. Male circumcision significantly reduces prevalence and load of genital anaerobic bacteria. MBio. 2013;4(2):e00076. https://doi.org/10.1128/mBio.00076-13.CrossRefPubMedPubMedCentral

89.

Mehta SD, Zhao D, Green SJ, Agingu W, Otieno F, Bhaumik R, Bhaumik D, Bailey RC. The microbiome composition of a man’s penis predicts incident bacterial vaginosis in his female sex partner with high accuracy. Frontiers in Cellular and Infection Microbiology 2020;10:433. https://doi.org/10.3389/fcimb.2020.00433.

90.

Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382(9907):1795–806. https://doi.org/10.1016/S0140-6736(13)61947-9.CrossRefPubMedPubMedCentral

91.

Tanton C, Geary RS, Clifton S, Field N, Heap KL, Mapp F, et al. Sexual health clinic attendance and non-attendance in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm Infect. 2018;94(4):268–76. https://doi.org/10.1136/sextrans-2017-053193.CrossRefPubMed

92.

Muzny CA, Pontius A, Woznicki N, Hudak KE, Lensing SY, Sobel JD, et al. Use of a novel couples’ verification tool in a male partner treatment study of women with recurrent bacterial vaginosis. Sex Transm Dis. 2020;47(12):e58–61. https://doi.org/10.1097/OLQ.0000000000001225.CrossRefPubMed

93.

Weinhardt LS, Forsyth AD, Carey MP, Jaworski BC, Durant LE. Reliability and validity of self-report measures of HIV-related sexual behavior: progress since 1990 and recommendations for research and practice. Arch Sex Behav. 1998;27(2):155–80. https://doi.org/10.1023/A:1018682530519.CrossRefPubMedPubMedCentral

94.

Schroder KE, Carey MP, Vanable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med. 2003;26(2):104–23. https://doi.org/10.1207/S15324796ABM2602_03.CrossRefPubMed

95.

Tourangeau R, Yan T. Sensitive questions in surveys. Psychol Bull. 2007;133(5):859–83. https://doi.org/10.1037/0033-2909.133.5.859.CrossRefPubMed

96.

DiClemente RJ, Sales JM, Danner F, Crosby RA. Association between sexually transmitted diseases and young adults’ self-reported abstinence. Pediatrics. 2011;127(2):208–13. https://doi.org/10.1542/peds.2009-0892.CrossRefPubMedPubMedCentral

97.

Wigan R, Vaughn C, Vodstrcil L, Doyle M, Kaiser M, McGuiness C, et al. “It’s just an issue and you deal with it... you just deal with it, you move on and you do it together.”: Men’s experiences of bacterial vaginosis and the acceptability of male partner treatment. PLoS One. 2020;15(6):e0235286.CrossRef

98.

Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(Suppl 1):S16–23. https://doi.org/10.1086/647939.CrossRefPubMed

99.

Sobel R, Sobel JD. Metronidazole for the treatment of vaginal infections. Expert Opin Pharmacother. 2015;16(7):1109–15. https://doi.org/10.1517/14656566.2015.1035255.CrossRefPubMed

100.

Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2004;191(4):1124–9. https://doi.org/10.1016/j.ajog.2004.05.033.CrossRefPubMed

101.

Kharsany AB, Hoosen AA, Van den Ende J. Antimicrobial susceptibilities of Gardnerella vaginalis. Antimicrob Agents Chemother. 1993;37(12):2733–5. https://doi.org/10.1128/AAC.37.12.2733.CrossRefPubMedPubMedCentral

102.

Simoes JA, Aroutcheva A, Heimler I, Shott S, Faro S. Bacteriocin susceptibility of Gardnerella vaginalis and its relationship to biotype, genotype, and metronidazole susceptibility. Am J Obstet Gynecol. 2001;185(5):1186–90. https://doi.org/10.1067/mob.2001.118144.CrossRefPubMed

103.

Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis. 2004;4(1):5. https://doi.org/10.1186/1471-2334-4-5.CrossRefPubMedPubMedCentral

104.

De Backer E, Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Temmerman M, et al. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. 2006;6(1):51. https://doi.org/10.1186/1471-2334-6-51.CrossRefPubMedPubMedCentral

105.

Nagaraja P. Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol. 2008;26(2):155–7. https://doi.org/10.4103/0255-0857.40531.CrossRefPubMed

106.

Alves P, Castro J, Sousa C, Cereija TB, Cerca N. Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model. J Infect Dis. 2014;210(4):593–6. https://doi.org/10.1093/infdis/jiu131.CrossRefPubMed

107.

Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. Diagn Microbiol Infect Dis. 2016;84(1):1–3. https://doi.org/10.1016/j.diagmicrobio.2015.10.006.CrossRefPubMed

108.

Swidsinski A, Dorffel Y, Loening-Baucke V, Schilling J, Mendling W. Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment. FEMS Immunol Med Microbiol. 2010;61(1):41–6. https://doi.org/10.1111/j.1574-695X.2010.00743.x.

109.

Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: an insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. Microb Pathog. 2019;127:21–30. https://doi.org/10.1016/j.micpath.2018.11.046.CrossRefPubMed

110.

Lee CY, Cheu RK, Lemke MM, Gustin AT, France MT, Hampel B, et al. Quantitative modeling predicts mechanistic links between pre-treatment microbiome composition and metronidazole efficacy in bacterial vaginosis. Nat Commun. 2020;11(1):6147. https://doi.org/10.1038/s41467-020-19880-w.CrossRefPubMedPubMedCentral

111.

Schwebke JR, Morgan FG, Jr., Koltun W, Nyirjesy P: A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):e678.e1–678.e9.

112.

De Backer E, Dubreuil L, Brauman M, Acar J, Vaneechoutte M. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect. 2010;16(5):470–2. https://doi.org/10.1111/j.1469-0691.2009.02852.x.CrossRefPubMed

113.

Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115–9. https://doi.org/10.1016/j.anaerobe.2017.05.005.CrossRefPubMedPubMedCentral

114.

Li T, Zhang Z, Wang F, He Y, Zong X, Bai H, et al. Antimicrobial susceptibility testing of metronidazole and clindamycin against Gardnerella vaginalis in planktonic and biofilm formation. Can J Infect Dis Med Microbiol. 2020;2020:1361825.PubMedPubMedCentral

115.

Sobel JD, Sobel R. Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opin Pharmacother. 2021; Ahead of print:1–8. https://doi.org/10.1080/14656566.2021.1904890.

116.

Gaspar C, Rolo J, Cerca N, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. Dequalinium chloride effectively disrupts bacterial vaginosis (BV) Gardnerella spp. biofilms. Pathogens. 2021;10(3):261.

117.

Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis. 2019;68(5):803–9. https://doi.org/10.1093/cid/ciy554.CrossRefPubMed

118.

Galiwango RM, Bagaya B, Mpendo J, Joag V, Okech B, Nanvubya A, et al. Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men. Trials. 2019;20(1):443. https://doi.org/10.1186/s13063-019-3545-7.CrossRefPubMedPubMedCentral

119.

Muzny CA, Schwebke JR. Asymptomatic bacterial vaginosis: to treat or not to treat? Curr Infect Dis Rep. 2020;22(12):32.

120.

U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Bacterial Vaginosis: Developing Drugs for Treatment, Guidance for Industry. 2019.

121.

Hillier SL, Nyirjesy P, Waldbaum AS, Schwebke JR, Morgan FG, Adetoro NA, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017;130(2):379–86. https://doi.org/10.1097/AOG.0000000000002135.CrossRefPubMed

122.

Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol. 2015;6:1528.PubMed

123.

Muzny CA, Schwebke JR. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis. 2015;61(4):601–6. https://doi.org/10.1093/cid/civ353.CrossRefPubMedPubMedCentral

124.

Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis: limitations and need for innovation. J Infect Dis. 2016;214(Suppl 1):S14–20. https://doi.org/10.1093/infdis/jiw159.CrossRefPubMedPubMedCentral

125.

Lev-Sagie A, Goldman-Wohl D, Cohen Y, Dori-Bachash M, Leshem A, Mor U, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019;25(10):1500–4. https://doi.org/10.1038/s41591-019-0600-6.CrossRefPubMed

126.

DeLong K, Bensouda S, Zulfiqar F, Zierden HC, Hoang TM, Abraham AG, et al. Conceptual design of a universal donor screening approach for vaginal microbiota transplant. Front Cell Infect Microbiol. 2019;9:306. https://doi.org/10.3389/fcimb.2019.00306.CrossRefPubMedPubMedCentral

127.

Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017;168(9-10):782–92. https://doi.org/10.1016/j.resmic.2017.04.001.CrossRefPubMed

128.

Armstrong-Buisseret L, Brittain C, David M, Dean G, Griffiths F, Hepburn T, et al. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials. 2019;20(1):648. https://doi.org/10.1186/s13063-019-3731-7.CrossRefPubMedPubMedCentral

Title: Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment
Authors: Lenka A. Vodstrcil
Christina A. Muzny
Erica L. Plummer
Jack D. Sobel
Catriona S. Bradshaw
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metronidazole
Clindamycin
Respiratory Microbiota
Published in: BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-021-02077-3

At a glance: The STEP trials

Springer Medicine

Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The rates and medical necessity of cesarean delivery in China, 2012–2019: an inspiration from Jiangsu

Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settings

Automated detection of lung nodules and coronary artery calcium using artificial intelligence on low-dose CT scans for lung cancer screening: accuracy and prognostic value

Functional connectivity changes in cerebral small vessel disease - a systematic review of the resting-state MRI literature

The positive externalities of migrant-based TB control strategy in a Chinese urban population with internal migration: a transmission-dynamic modeling study

Estimating the annual dengue force of infection from the age of reporting primary infections across urban centres in endemic countries